Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Imago Biosciences Inc
(NQ:
IMGO
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Jan 10, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Imago Biosciences Inc
Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.
December 12, 2022
From
Merck & Co., Inc.
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Apollo Endosurgery, Inc. (Nasdaq - APEN), Imago BioSciences, Inc. (Nasdaq - IMGO), Opiant Pharmaceuticals Inc. (Nasdaq - OPNT), Benefitfocus, Inc. (Nasdaq - BNFT)
December 05, 2022
From
Brodsky & Smith LLC
Via
GlobeNewswire
IMAGO BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Imago BioSciences, Inc. - IMGO
November 22, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
TC BioPharm Ltd ($TCBP) leads fight against Acute myeloid leukemia with its cell therapy product OmnImmune
November 22, 2022
Via
AB Newswire
Topics
Death
Economy
Stocks
Exposures
COVID-19
Death
Interest Rates
Imago BioSciences (NASDAQ: IMGO) to be Acquired by Merck (NYSE: MRK) for $1.35 Billion
November 21, 2022
Imago BioSciences, Inc. (NASDAQ: IMGO) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development
Via
Spotlight Growth
IMGO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Imago BioSciences, Inc. Is Fair to Shareholders
November 21, 2022
From
Halper Sadeh LLC
Via
Business Wire
Merck to Acquire Imago BioSciences, Inc.
November 21, 2022
From
Merck & Co., Inc.
Via
Business Wire
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2021
December 12, 2021
From
Imago BioSciences
Via
Business Wire
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2021
December 11, 2021
From
Imago BioSciences, Inc.
Via
Business Wire
Imago BioSciences Appoints Laurie Keating to Board of Directors
November 18, 2021
From
Imago BioSciences, Inc.
Via
Business Wire
Imago BioSciences Announces Oral Data Presentations at the Upcoming 63rd American Society of Hematology Annual Meeting and Exposition
November 04, 2021
From
Imago BioSciences, Inc.
Via
Business Wire
Imago BioSciences Announces Its Addition to the Russell 2000® Index
September 20, 2021
From
Imago BioSciences, Inc.
Via
Business Wire
Imago BioSciences Reports Second Quarter 2021 Financial Results and Provides Recent Business Updates
August 19, 2021
From
Imago BioSciences, Inc.
Via
Business Wire
Imago BioSciences Receives Orphan Designation From European Medicines Agency for Bomedemstat for the Treatment of Essential Thrombocythemia
July 30, 2021
From
Imago BioSciences
Via
Business Wire
Imago BioSciences, Inc. Announces Exercise of Underwriters’ Option to Purchase Additional Shares
July 26, 2021
From
Imago BioSciences, Inc.
Via
Business Wire
Imago BioSciences, Inc. Announces Closing of $134.4 Million Initial Public Offering
July 20, 2021
From
Imago BioSciences, Inc.
Via
Business Wire
Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock
July 15, 2021
From
Imago BioSciences, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.